BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30243944)

  • 1. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ethylene glycol)-induced and temperature-dependent phase separation in fluid binary phospholipid membranes.
    Lehtonen JY; Kinnunen PK
    Biophys J; 1995 Feb; 68(2):525-35. PubMed ID: 7696506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
    Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
    Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R; Mayer LD
    Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
    Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
    J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
    Krishna R; St-Louis M; Mayer LD
    Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior.
    Mohammadi ZA; Aghamiri SF; Zarrabi A; Talaie MR
    Curr Drug Deliv; 2016; 13(7):1065-1070. PubMed ID: 26708673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of transition metal-doxorubicin complexes inside liposomes.
    Abraham SA; Edwards K; Karlsson G; MacIntosh S; Mayer LD; McKenzie C; Bally MB
    Biochim Biophys Acta; 2002 Sep; 1565(1):41-54. PubMed ID: 12225851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
    Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
    Harasym TO; Cullis PR; Bally MB
    Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.
    Boakye CH; Patel K; Singh M
    Int J Pharm; 2015 Jul; 489(1-2):106-16. PubMed ID: 25910414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.
    Lee CC; Gillies ER; Fox ME; Guillaudeu SJ; Fréchet JM; Dy EE; Szoka FC
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16649-54. PubMed ID: 17075050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.